Literature DB >> 3329746

Predominance of locally-produced prostaglandin E2 over prostacyclin in skin incisions in man.

J M Ritter1, S E Barrow, P L Smith, K M Taylor, C T Dollery.   

Abstract

Blood was collected from skin incisions made by the 'Simplate' technique in 8 healthy men. Prostaglandin (PG) E2, but not 6-oxo-PGF1 alpha, the stable hydrolysis product of prostacyclin (PGI2), was tentatively identified using capillary column gas chromatography/electron capture mass spectrometry. It was not possible to quantify PGE2 because of the small volumes of blood generated by this method. Larger blood samples were then collected from 22 skin incisions in 13 patients undergoing cardiothoracic surgery. Concentrations of PGE2 were substantially greater than 6-oxo-PGF1 alpha in every sample. 13,14-Dihydro-15-oxo-PGF2 alpha, a pulmonary metabolite of PGE2, was not elevated, indicating that the PGE2 was synthesised locally at the site of incision. In 6 further patients undergoing cardiac surgery, blood sampled from an antecubital vein before and during operation contained little or no PGE2. We conclude that a substantial proportion of the PGE2 in blood emerging from skin incisions may be formed locally by the traumatised microvessels, consistent with the hypothesis that PGE2 is the principle prostaglandin synthesised by human cutaneous microvessels in vivo.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3329746     DOI: 10.1016/0090-6980(87)90067-0

Source DB:  PubMed          Journal:  Prostaglandins        ISSN: 0090-6980


  2 in total

1.  Effects of a selective thromboxane receptor antagonist (GR32191B) and of glyceryl trinitrate on bleeding time in man.

Authors:  J M Ritter; N Benjamin; H S Doktor; S E Barrow; T G Mant; S Schey; P Stewart-Long
Journal:  Br J Clin Pharmacol       Date:  1990-04       Impact factor: 4.335

2.  Differential effect of aspirin on thromboxane and prostaglandin biosynthesis in man.

Authors:  J M Ritter; J R Cockcroft; H S Doktor; J Beacham; S E Barrow
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.